Overview

Efficacy and Safety of the RD Regimen(Lenalidomide, Dexamethasone) for Rosai-Dorfman Disease

Status:
RECRUITING
Trial end date:
2027-04-12
Target enrollment:
Participant gender:
Summary
In patients with Rosai-Dorfman disease (RDD), a treatment regimen of lenalidomide combined with dexamethasone is planned to be used.
Phase:
PHASE2
Details
Lead Sponsor:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Treatments:
Dexamethasone
Lenalidomide